Aliyah Pabani

TL;DR: Atezolizumab plus carboplatin and nab-paclitaxel could be a potential neoadjuvant regimen for resectable non-small-cell lung cancer, with a high proportion of patients achieving a major pathological response, and manageable treatment-related toxic effects, which did not compromise surgical resection.

TL;DR: Most ircAEs responded to symptom- and phenotype-directed dermatologic therapies, whereas biologic therapies were effective in patients with corticosteroid-refractory disease, and they may represent actionable therapeutic targets for immune-related skin toxicities.

TL;DR: Improved education, appropriate supportive care and dosing should allow more patients to maximally and safely benefit from brigatinib, and Adapting the EOPE nomenclature to include the word 'transient' (TEOPEs) may further clinician and patient understanding in distinguishing these events from the pneumonitis seen with other TKIs.

TL;DR: In this article , the authors showed that despite increased hospitalization, immune-related adverse events are associated with longer survival among patients receiving combination immune checkpoint blockade, while resuming immunotherapy may benefit selected patients.

TL;DR: This case is unique as it describes the evolution of an invasive ductal carcinoma after treatment into a SCC of the breast, and it is speculated that the initial treatment allowed a minority of treatment-resistant neuroendocrine cells to grow and become the dominant face of the tumor.